Objective To define potential factors that could predict concomitant neoplastic diseases in
patients diagnosed with PM/DM, which could inform screening decisions. Methods Two …

Abstract Knowledge on idiopathic inflammatory myopathy (IIM) has evolved with the
identification of myositis-associated and myositis-specific antibodies, development of …

Objectives. To determine the longitudinal trends in serum levels of four myositis-associated
autoantibodies: anti-Jo-1,-transcription intermediary factor 1 γ (TIF1-γ),-signal recognition …

Background Autoantibodies against transcriptional intermediary factor 1 (TIF1) and Mi-2 are
selectively detected in patients with dermatomyositis (DM). To measure these antibodies …

Idiopathic inflammatory myopathies represent still a diagnostic and therapeutic challenge in
different disciplines including neurology, rheumatology, and dermatology. In recent years …

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases
traditionally defined by clinical manifestations including skeletal muscle weakness, skin …

Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by skin
eruptions and myositis. Anti‐transcriptional intermediary factor 1‐γ antibody (anti‐TIF1‐γ Ab) …

Objectives Anti‐TIF1-gamma autoantibodies can be detected with immunoprecipitation (IP),
line blot (LB) and ELISA. We compared assay performance in patients with DM and the …

Objectives The objective of the current study was to detect plasma profiles of inflammatory
cytokines for determining potential biomarkers indicating cancer presence among the anti …

Abstract Introduction Myositis-specific autoantibodies (MSAs) are thought to be mutually
exclusive in patients with idiopathic inflammatory myopathies (IIM) based on studies with …